CompletedNot Applicable

Evaluation of Long Coronary Artery Stents With Third-generation Dual-source Computed Tomography Angiography

Finland45 participantsStarted 2023-01-16

Plain-language summary

The goal of this clinical trial is to assess third-generation dual-source coronary computed tomography angiography (CCTA) performance in the evaluation of long coronary stents in patients with coronary artery chronic total occlusions. The main questions it aims to answer are: * Can patency of long coronary artery stents be assessed with third generation CCTA? * What are the factors affecting the assessability? * What is the radiation exposure of third generation CCTA?

Who can participate

Age range

75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Surviving patients with a CTO PCI minimum of four years prior to the study date * Successful CTO PCI with a drug-eluting stent * Primary procedure minimum of four years prior to study date * CTO stent length ≥ 38 mm in right coronary artery (RCA) and left anterior descending (LAD) coronary artery * CTO stent length ≥ 30 mm in left circumflex coronary artery (LCX). The definition is clinical. * Age at primary procedure ≤ 75 years * Communication in English, Finnish or Swedish Exclusion Criteria: * Malignancy with poor prognosis or ongoing diagnostics * Significantly impaired performance in daily activities * Significant psychiatric disorder * Active alcohol or drug abuse * Memory disorder or other cognitive impairment * Primary procedure in-stent CTO PCI * Target vessel revascularisation or CABG after the primary - procedure * Glomerular filtration rate ≤40 ml/min * ICA or CCTA less than six months prior to the study date

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Stent patency assesment with third-generation dual-source CCTA

Timeframe: up to 7.3 months (maximum time between CCTA and ICA)

Trial details

NCT IDNCT06543641

SponsorLauri Mansikkaniemi

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-11-10

View on ClinicalTrials.gov More Coronary Artery Disease trials